A Phase 3 Study of Eltrombopag vs. Standard First-Line Management for Newly Diagnosed Immune Thrombocytopenia (ITP) in Children
K
Kerry Hege, MD
Primary Investigator
Not Recruiting
1 years - 17 years
All
Phase
N/A
1 Location
Brief description of study
The purpose of this study is to determine if Eltrombopag is as effective of a treatment for patients with newly diagnosed Immune Thrombocytopenia (ITP) when compared to standard treatment.
Detailed description of study
Participants will not be paid for their participation.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Immune Thrombocytopenia
-
Age: 1 years - 17 years
-
Gender: All
Inclusion Criteria
Newly diagnosed ITP (<3 months from diagnosis (first abnormal platelet count)
Requires pharmacologic treatment from the perspective of the treating clinician.
Requires pharmacologic treatment from the perspective of the treating clinician.
Updated on
01 Aug 2024.
Study ID: 1905858882 (PHO-BAYLOR-ICON3)
